Crowley Wealth Management Inc. Acquires Shares of 50 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Crowley Wealth Management Inc. bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 50 shares of the biopharmaceutical company’s stock, valued at approximately $36,000.

Several other institutional investors and hedge funds also recently made changes to their positions in REGN. FSA Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $26,000. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 15 shares during the last quarter. Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Finally, Private Wealth Management Group LLC grew its position in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 39 shares during the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of several research reports. Sanford C. Bernstein decreased their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Bernstein Bank reduced their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Truist Financial reduced their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Finally, Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $973.13.

Regeneron Pharmaceuticals Stock Down 0.6 %

Shares of REGN opened at $658.48 on Monday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The stock has a market capitalization of $71.99 billion, a price-to-earnings ratio of 17.20, a PEG ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a fifty day moving average of $689.43 and a 200-day moving average of $813.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. During the same period in the prior year, the company earned $11.86 EPS. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.53%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.